336 related articles for article (PubMed ID: 24829206)
21. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
[TBL] [Abstract][Full Text] [Related]
22. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
[TBL] [Abstract][Full Text] [Related]
23. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
[TBL] [Abstract][Full Text] [Related]
25. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice.
Brown BD; Shi CX; Rawle FE; Tinlin S; McKinven A; Hough C; Graham FL; Lillicrap D
J Thromb Haemost; 2004 Jan; 2(1):111-8. PubMed ID: 14717974
[TBL] [Abstract][Full Text] [Related]
26. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
27. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.
Scallan CD; Liu T; Parker AE; Patarroyo-White SL; Chen H; Jiang H; Vargas J; Nagy D; Powell SK; Wright JF; Sarkar R; Kazazian HH; McClelland A; Couto LB
Blood; 2003 Dec; 102(12):3919-26. PubMed ID: 12893764
[TBL] [Abstract][Full Text] [Related]
28. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.
McCORMACK WM; Seiler MP; Bertin TK; Ubhayakar K; Palmer DJ; Ng P; Nichols TC; Lee B
J Thromb Haemost; 2006 Jun; 4(6):1218-1225. PubMed ID: 16706963
[TBL] [Abstract][Full Text] [Related]
29. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
Matsui H; Hegadorn C; Ozelo M; Burnett E; Tuttle A; Labelle A; McCray PB; Naldini L; Brown B; Hough C; Lillicrap D
Mol Ther; 2011 Apr; 19(4):723-30. PubMed ID: 21285959
[TBL] [Abstract][Full Text] [Related]
30. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
[TBL] [Abstract][Full Text] [Related]
31. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.
Finn JD; Ozelo MC; Sabatino DE; Franck HW; Merricks EP; Crudele JM; Zhou S; Kazazian HH; Lillicrap D; Nichols TC; Arruda VR
Blood; 2010 Dec; 116(26):5842-8. PubMed ID: 20876851
[TBL] [Abstract][Full Text] [Related]
32. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
Gallo-Penn AM; Shirley PS; Andrews JL; Kayda DB; Pinkstaff AM; Kaloss M; Tinlin S; Cameron C; Notley C; Hough C; Lillicrap D; Kaleko M; Connelly S
Hum Gene Ther; 1999 Jul; 10(11):1791-802. PubMed ID: 10446919
[TBL] [Abstract][Full Text] [Related]
33. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
Patel SR; Lundgren TS; Spencer HT; Doering CB
Front Immunol; 2020; 11():494. PubMed ID: 32351497
[TBL] [Abstract][Full Text] [Related]
34. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.
Matsui H; Fujimoto N; Sasakawa N; Ohinata Y; Shima M; Yamanaka S; Sugimoto M; Hotta A
PLoS One; 2014; 9(8):e104957. PubMed ID: 25126862
[TBL] [Abstract][Full Text] [Related]
35. Codon optimization of human factor VIII cDNAs leads to high-level expression.
Ward NJ; Buckley SM; Waddington SN; Vandendriessche T; Chuah MK; Nathwani AC; McIntosh J; Tuddenham EG; Kinnon C; Thrasher AJ; McVey JH
Blood; 2011 Jan; 117(3):798-807. PubMed ID: 21041718
[TBL] [Abstract][Full Text] [Related]
36. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
Kootstra NA; Matsumura R; Verma IM
Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
[TBL] [Abstract][Full Text] [Related]
37. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.
Connelly S; Andrews JL; Gallo AM; Kayda DB; Qian J; Hoyer L; Kadan MJ; Gorziglia MI; Trapnell BC; McClelland A; Kaleko M
Blood; 1998 May; 91(9):3273-81. PubMed ID: 9558383
[TBL] [Abstract][Full Text] [Related]
38. Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells.
Herder C; Tonn T; Oostendorp R; Becker S; Keller U; Peschel C; Grez M; Seifried E
Arterioscler Thromb Vasc Biol; 2003 Dec; 23(12):2266-72. PubMed ID: 14551158
[TBL] [Abstract][Full Text] [Related]
39. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes.
Andrews JL; Weaver L; Kaleko M; Connelly S
Haemophilia; 1999 May; 5(3):160-8. PubMed ID: 10444282
[TBL] [Abstract][Full Text] [Related]
40. Immune response to FVIII in hemophilia A: an overview of risk factors.
Ghosh K; Shetty S
Clin Rev Allergy Immunol; 2009 Oct; 37(2):58-66. PubMed ID: 19148784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]